Safety of and Immune Response of a 2-Dose Regimen of rDEN1delta30 Dengue Virus Vaccine - Related Studies

Safety of and Immune Response of a 2-Dose Regimen of rDEN1delta30 Dengue Virus Vaccine

This study is currently recruiting participants.

Study NCT00473135. Last updated on January 15, 2008. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Dengue

2	Additional conditions recognized in this trial
		Dengue Hemorrhagic Fever

3	More general conditions related to this trial
		Arbovirus Infections
		Flaviviridae Infections
		Flavivirus Infections
		Hemorrhagic Fevers, Viral
		RNA Virus Infections
		Virus Diseases

4	Interventions listed in this trial
		rDEN1delta30
		Placebo

5	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)
		Center for Immunization Research